Clinical studies on tazobactam/piperacillin

A clinical study was carried out on a new drug combination, tazobactam/piperacillin (TAZ/PIPC), i. e. tazobactam (TAZ) and piperacillin (PIPC) 1: 4. The results were as follows: Nine respiratory tract infections were treated with TAZ/PIPC. The dosage was 5 g per day for 6-20days. Six of 9 assessable...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 42; no. Supplement2; pp. 733 - 737
Main Authors Yamanaka, Yoshitaka, Yonezu, Seibun, Yasunaga, Kojiro
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1994
Online AccessGet full text

Cover

More Information
Summary:A clinical study was carried out on a new drug combination, tazobactam/piperacillin (TAZ/PIPC), i. e. tazobactam (TAZ) and piperacillin (PIPC) 1: 4. The results were as follows: Nine respiratory tract infections were treated with TAZ/PIPC. The dosage was 5 g per day for 6-20days. Six of 9 assessable cases responded well to the therapy. Klebsiella pneumoniae isolated from the respiratory tract before therapy was eradicated. As to side effects and abnormalities in laboratory findings, abdominal fullness was found in 1 case and slight elevation of GOT and GPT was found in 1 case.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.42.Supplement2_733